Get the Stockscreener App
189.49
0.40%
-0.77
After Hours:
189.49
Overview
News
Price History
Option Chain
Financials
Discussions
Forecast
Stock Split
Dividend History
Quest Diagnostics Inc stock is traded at $189.49, with a volume of 1.13M.
It is down -0.40% in the last 24 hours and up +6.06% over the past month.
Quest Diagnostics is a leading independent provider of diagnostic testing, information, and services in the US. The company generates over 95% of its revenue through clinical testing, anatomic pathology, esoteric testing, and substance abuse testing with specimens collected at its national network of roughly 2,300 patient service centers, as well as multiple doctors offices and hospitals. The firm also runs a much smaller diagnostic solutions segment that provides clinical trials testing, risk-assessment services, and information technology solutions.
See More
Previous Close:
$190.26
Open:
$189.4
24h Volume:
1.13M
Relative Volume:
1.06
Market Cap:
$21.08B
Revenue:
$10.52B
Net Income/Loss:
$999.00M
P/E Ratio:
22.66
EPS:
8.3628
Net Cash Flow:
$1.22B
1W Performance:
+8.63%
1M Performance:
+6.06%
6M Performance:
+13.45%
1Y Performance:
+24.94%
1-Day Range:
$188.75
$190.96
1-Week Range:
$173.51
$190.99
52-Week Range:
$150.14
$197.55
Quest Diagnostics Inc Stock (DGX) Company Profile
Name
Quest Diagnostics Inc
Sector
Industry
Phone
(973) 520-2700
Address
500 PLAZA DRIVE, SECAUCUS
Compare DGX with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
DGX
Quest Diagnostics Inc
|
189.49 | 21.16B | 10.52B | 999.00M | 1.22B | 8.3628 |
|
TMO
Thermo Fisher Scientific Inc
|
618.72 | 234.69B | 43.74B | 6.58B | 6.11B | 17.31 |
|
DHR
Danaher Corp
|
235.99 | 169.45B | 24.27B | 3.50B | 5.02B | 4.8589 |
|
IDXX
Idexx Laboratories Inc
|
715.37 | 56.86B | 4.17B | 1.03B | 940.22M | 12.61 |
|
IQV
Iqvia Holdings Inc
|
237.68 | 41.09B | 15.90B | 1.28B | 2.21B | 7.2842 |
|
A
Agilent Technologies Inc
|
139.64 | 41.06B | 6.95B | 1.30B | 1.15B | 4.5696 |
Quest Diagnostics Inc Stock (DGX) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Aug-25-25 | Downgrade | Robert W. Baird | Outperform → Neutral |
| Apr-02-25 | Initiated | Redburn Atlantic | Buy |
| Mar-04-25 | Downgrade | Citigroup | Buy → Neutral |
| Jan-06-25 | Upgrade | Leerink Partners | Market Perform → Outperform |
| Dec-17-24 | Upgrade | Morgan Stanley | Equal-Weight → Overweight |
| Dec-10-24 | Resumed | Jefferies | Buy |
| Oct-23-24 | Upgrade | Robert W. Baird | Neutral → Outperform |
| Aug-28-24 | Resumed | Evercore ISI | In-line |
| Jul-10-24 | Upgrade | Citigroup | Neutral → Buy |
| Feb-26-24 | Initiated | Leerink Partners | Market Perform |
| Feb-07-24 | Upgrade | Jefferies | Hold → Buy |
| Jan-03-24 | Initiated | Barclays | Equal Weight |
| Dec-12-23 | Upgrade | BofA Securities | Neutral → Buy |
| Jun-29-23 | Initiated | Piper Sandler | Neutral |
| May-02-23 | Downgrade | BofA Securities | Buy → Neutral |
| Apr-03-23 | Upgrade | Citigroup | Sell → Neutral |
| Jan-23-23 | Initiated | Evercore ISI | In-line |
| Nov-17-22 | Downgrade | Citigroup | Neutral → Sell |
| Aug-22-22 | Resumed | Morgan Stanley | Equal-Weight |
| Apr-04-22 | Downgrade | Citigroup | Buy → Neutral |
| Feb-23-22 | Downgrade | UBS | Buy → Neutral |
| Feb-02-22 | Downgrade | Jefferies | Buy → Hold |
| Jan-28-22 | Downgrade | Deutsche Bank | Buy → Hold |
| May-04-21 | Upgrade | UBS | Neutral → Buy |
| Mar-12-21 | Downgrade | Robert W. Baird | Outperform → Neutral |
| Oct-21-20 | Upgrade | Argus | Hold → Buy |
| Jul-29-20 | Upgrade | KeyBanc Capital Markets | Sector Weight → Overweight |
| Jul-14-20 | Upgrade | BofA Securities | Neutral → Buy |
| Jun-09-20 | Upgrade | Wells Fargo | Underweight → Equal Weight |
| Jun-02-20 | Upgrade | Deutsche Bank | Hold → Buy |
| Apr-28-20 | Upgrade | Morgan Stanley | Equal-Weight → Overweight |
| Apr-27-20 | Upgrade | Citigroup | Neutral → Buy |
| Apr-27-20 | Upgrade | Wolfe Research | Underperform → Peer Perform |
| Mar-27-20 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| Jan-08-20 | Initiated | Wells Fargo | Underweight |
| Jan-07-20 | Downgrade | Barclays | Overweight → Equal Weight |
| Dec-19-19 | Upgrade | BofA/Merrill | Underperform → Neutral |
| Jul-15-19 | Downgrade | Goldman | Neutral → Sell |
| Apr-02-19 | Upgrade | Jefferies | Hold → Buy |
| Mar-18-19 | Resumed | Credit Suisse | Neutral |
| Jan-31-19 | Downgrade | Argus | Buy → Hold |
| Jan-17-19 | Initiated | UBS | Neutral |
| Jan-03-19 | Downgrade | BofA/Merrill | Neutral → Underperform |
| Dec-03-18 | Downgrade | BofA/Merrill | Buy → Neutral |
| Nov-30-18 | Downgrade | Goldman | Buy → Neutral |
View All
Quest Diagnostics Inc Stock (DGX) Latest News
How Do Investors Really Feel About Quest Diagnostics Inc? - Benzinga
TKG Advisors LLC Raises Stake in Quest Diagnostics Incorporated $DGX - MarketBeat
Nordea Investment Management AB Trims Holdings in Quest Diagnostics Incorporated $DGX - MarketBeat
Aug PreEarnings: Is Quest Diagnostics Incorporated stock a value trapWatch List & AI Optimized Trade Strategies - baoquankhu1.vn
Quest Diagnostics Inc. (NYSE:DGX): A Prime Pick for Steady, Growing Dividends - Chartmill
Manning & Napier Advisors LLC Sells 11,341 Shares of Quest Diagnostics Incorporated $DGX - MarketBeat
Market Rankings: What are Quest Diagnostics Incorporateds earnings expectationsJuly 2025 Market Mood & Daily Technical Stock Forecast Reports - baoquankhu1.vn
Baird Adjusts Quest Diagnostics Price Target to $203 From $198, Maintains Neutral Rating - marketscreener.com
Quest Diagnostics Incorporated $DGX Shares Purchased by Nisa Investment Advisors LLC - MarketBeat
Best Testosterone Replacement Therapy (TRT) 2026: Taurus Meds Consumer Analysis Examines Online TRT Access and At-Home Testosterone Treatment Options - GlobeNewswire Inc.
SG Americas Securities LLC Sells 19,597 Shares of Quest Diagnostics Incorporated $DGX - MarketBeat
Is Quest Diagnostics (DGX) Stock Outpacing Its Medical Peers This Year? - Eastern Progress
Quest Diagnostics About To Put More Money In Your Pocket (DGX) - Nasdaq
How cyclical is Quest Diagnostics Incorporated (QDI) stock compared to rivalsGDP Growth & Free Safe Capital Growth Stock Tips - Улправда
Visby Engages Quest and Labcorp to Broaden Consumer Access to First At-Home, FDA-Authorized PCR Test for STIs - BioSpace
Quest Diagnostics to Release Fourth Quarter and Full Year 2025 Financial Results on February 10, 2026 - Finviz
Can Quest Diagnostics Incorporated stock sustain institutional interestJuly 2025 PostEarnings & Verified Swing Trading Watchlists - Улправда
New 30-minute at-home test helps women detect STIs privately - Stock Titan
Caldwell Trust Co Grows Holdings in Quest Diagnostics Incorporated $DGX - MarketBeat
Quest Diagnostics Incorporated (NYSE:DGX) Given Consensus Recommendation of "Hold" by Brokerages - MarketBeat
Is It Time To Reassess Quest Diagnostics (DGX) After Recent Share Price Strength? - Yahoo Finance
Quest Diagnostics (DGX) is a Top-Ranked Growth Stock: Should You Buy? - Nasdaq
Data Featuring Haystack MRD from Quest Diagnostics to be Presented at the 2026 ASCO Gastrointestinal Cancers Symposium - Finviz
Data Featuring Haystack MRD® from Quest Diagnostics to be Presented at the 2026 ASCO Gastrointestinal Cancers Symposium - MarketScreener
Data Featuring Haystack MRD® from Quest Diagnostics to be Presented at the 2026 ASCO Gastrointestinal Cancers Symposium – Company AnnouncementFT.com - Financial Times
Assessing Quest Diagnostics (DGX) Valuation After Recent Share Price Momentum And Perceived Undervaluation - Yahoo Finance
Corewell Health, Quest Diagnostics form joint venture - Modern Healthcare
Quest Diagnostics, Corewell Health Complete Laboratory JV in Michigan - MarketScreener
Palmetto Grain Brokerage - Palmetto Grain Brokerage
Corewell Health and Quest Diagnostics Complete Laboratory Joint Venture Transaction in Michigan - Finviz
What You Need To Know Ahead of Quest Diagnostics' Earnings Release - Barchart.com
Quest Diagnostics Incorporated $DGX Shares Sold by SteelPeak Wealth LLC - MarketBeat
Quest Diagnostics Find A Testfav Events Billing & Coding- - shababeek.org
RSI Alert: Quest Diagnostics Now Oversold - Nasdaq
Quest Diagnostics Incorporated $DGX Shares Purchased by Braun Stacey Associates Inc. - MarketBeat
Ethic Inc. Increases Stock Holdings in Quest Diagnostics Incorporated $DGX - MarketBeat
Q3 Earnings Highlights: Quest (NYSE:DGX) Vs The Rest Of The Testing & Diagnostics Services Stocks - Finviz
Boston Trust Walden Corp Sells 53,026 Shares of Quest Diagnostics Incorporated $DGX - MarketBeat
Quest Diagnostics (DGX) Upgraded to Buy: Here's Why - Yahoo Finance
Copeland Capital Management LLC Sells 7,889 Shares of Quest Diagnostics Incorporated $DGX - MarketBeat
Harbor Capital Advisors Inc. Has $596,000 Stake in Quest Diagnostics Incorporated $DGX - MarketBeat
Pacer Advisors Inc. Grows Stock Holdings in Quest Diagnostics Incorporated $DGX - MarketBeat
Assenagon Asset Management S.A. Lowers Stake in Quest Diagnostics Incorporated $DGX - MarketBeat
Is Quest Diagnostics Stock a Right Pick for Your Portfolio Now? - sharewise.com
Quest Diagnostics Incorporated $DGX Shares Sold by Coho Partners Ltd. - MarketBeat
Voya Investment Management LLC Reduces Stock Holdings in Quest Diagnostics Incorporated $DGX - MarketBeat
Thrivent Financial for Lutherans Purchases 11,351 Shares of Quest Diagnostics Incorporated $DGX - MarketBeat
Corient Private Wealth LLC Has $4.49 Million Stake in Quest Diagnostics Incorporated $DGX - MarketBeat
What is the fair value of Quest Diagnostics Incorporated stock now2025 Bull vs Bear & Expert Curated Trade Setups - Улправда
Quest Diagnostics to Speak at the 44th Annual J.P. Morgan Healthcare Conference - PR Newswire
Quest Diagnostics Incorporated's (NYSE:DGX) Fundamentals Look Pretty Strong: Could The Market Be Wrong About The Stock? - Yahoo Finance
Quest Diagnostics Inc Stock (DGX) Financials Data
Revenue
Net Income
Cash Flow
EPS
2.51%
0.74%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):